Home
Choose language  
Pharmacoreport Pharmacoreport
www.pharmacoreport .com is a news site providing information about the top international pharmaceutical companies. This website will also provide other information about these pharmaceuticals like their address and locations, corporate history, clinical trials, annual report, employees, careers and jobs, health care products, research, sales, shares, dividend & stock price, and patients’ assistance program.
 
AMGen   AMGen

 


AMGen Incorporation is the global biotechnology enterprise which was established in the year 1980. The headquarters of AMGen Inc. are situated at the Newbury Park – the part of Thousand Oaks in California – the United States. The company is supposed to be the biggest autonomous biotechnology enterprise which employs around 15,000 people.

The term AMGen is the combination of the original name of the company which broadly denotes Applied Molecular Genetics which gradually became the formal name of the company during 1983 – precisely 3 years of the company’s incorporation as well as the first ever public offerings inadvertently.  

AMGen is also reported to have strong history of taking over a few of the most leading corporate enterprises such as: Synergen Inc during 1994, Kinetix Pharmaceuticals Inc during 2000, Immunex Corporation during 2002, Tularik Inc during 2004, Abgenix Inc during 2006, Avidia Inc also during 2006, Ilypsa Inc and Alantos Pharmaceuticals Holdings Inc both during the current year i.e. 2007. 

It is reported that for poising as the most future-oriented enterprise, Business Week has AMGen in the 4th position on the S&P 500 on the strength of ratio calculations made apparently on research and development expenses or budgets along with capital spending, and the total outlays by the contenders. AMGen showed the fourth highest ratio figuring as 506:1000. The company is also the member of the Pennsylvania Bio Commerce Organization.

The major products of AMGen include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Senispar and Mimpara of which Epogen and Neupogen were the first two biopharmaceutical products of the company when they were launched in the markets. 


Ganentech , Eishai Co , Daichi Pharmaceutical Co , Biogan Idec , Wetson Pharmaceuticals , Glaksosmithkline , Schereeng_Plough , H Lundback , Bohringer Ingelheim , Ganzyme
Latest News About amgen
COMPANY NEWS; Amgen Backed In Patent Case
Amgen appealed has, and the three judge requests chalkboards granted a stay, noticing that andandAmgen showed, that numerous, complicated and essential arguments.....More
Amgen vs. J&J: Will It Ever End?
Debate old a seventeen year between biotech-pioneer Amgen inc. and tremendously Johnson... Its roots go develops back to 1985, when Amgen a box-office hit. hat...More
Susquehanna Inv. Group v. Amgen Boulder, Inc.,Susquehanna Inv. Group...
Accused Amgen boulders, inc. (Amgen), earlier well known as a Synergen, ... They maintain that Amgen and certain directors and officer (the individual.....More
Amgen: Up from Biotech
When Sharer came to Amgen, when president and chief that officer in 1992 serve, ... and Amgen, all of 22 years old, will be incorporated with firms that for that.....More
First Witness Takes Stand in Amgen Biotechnology Patent Case.
Amgen, is based in thousand oaks, Calif., became the nationand the largest biotech-firm because of its success developing and sale Epogen. .....More
Amgen net edges higher; anemia, arthritis treatments sales rise -...
On that basis, Amgen became to earn 95 cents a share on incomes of $3.77,. erwartet. Regard ahead, has Amgen prediction the salaries of 2007 from $4.30 to $4.50 a. on place....More
Wall Street Vision: Thin Genes, Fat Profits; Amgen& Protein...
Tests successful the messages by Amgen Inc.and of a white... Researchers at Amgen wrote an of three paper to be published Friday in that, .....More
Amgen Deal Not Good Enough
Amgen says, buy becomes that it Immunex for $16.7 billions, and that combines companyand.. Amgen offers 0.44 shares and $4.50 in cashola for every Immunex share in. .....More
Fool.com: Buying Amgen (Rule Breaker Buy Report) December 15, 1998
Therefore itand time for us, something of Amgen gmbh to buying, (Nasdaq: AMGN). ... And now, Amgen. Is what this? are we, who find too many large firms in that of a share, .....More
Two Drugs in a New Class Pass a Major FDA Hurdle
The new drugs that by two biotechnology firms are developed Amgen inc. and that... Amgen said, received have that 250000 new Krebsepatienten chemotherapy each year.....More